Antibody‐directed myostatin inhibition in 21‐mo‐old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Sarcopenia is the progressive loss of skeletal muscle mass and function with advancing age, leading to reduced mobility and quality of life. We tested the hypothesis that antibody‐directed myostatin inhibition would attenuate the decline in mass and function of muscles of aged mice and that apoptosis would be reduced. Eighteen‐month‐old C57BL/6 mice were treated for 14 wk with a once‐weekly injection of saline (control, n =9) or a mouse chimera of anti‐human myostatin antibody (PF‐354, 10 mg/kg; n =12). PF‐354 prevented the age‐related reduction in body mass and increased soleus, gastrocnemius, and quadriceps muscle mass ( P <0.05). PF‐354 increased fiber cross‐sectional area by 12% and enhanced maximum in situ force of tibialis anterior (TA) muscles by 35% ( P <0.05). PF‐354 increased the proportion of type IIa fibers by 114% ( P <0.01) and enhanced activity of oxidative enzymes (SDH) by 39% ( P <0.01). PF‐354 reduced markers of apoptosis in TA muscle cross‐sections by 56% ( P <0.03) and reduced caspase3 mRNA by 65% ( P <0.04). Antibody‐directed myostatin inhibition attenuated the decline in mass and function of muscles of aging mice, in part, by reducing apoptosis. These observations identify novel roles for myostatin in regulation of muscle mass and highlight the therapeutic potential of antibody‐directed myostatin inhibition for sarcopenia.—Murphy, K. T., Koopman, R., Naim, T., Léger, B., Trieu, J., Ibebunjo, C. Lynch, G. S. Antibody‐directed myostatin inhibition in 21‐mo‐old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J . 24, 4433–4442 (2010). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Invited Review: Aging and sarcopenia
Doherty, T. J. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00347.2003 · Cited by 1,764
Mutations in myostatin ( GDF8 ) in Double-Muscled Belgian Blue and Piedmontese Cattle
Kambadur, R., Sharma, M., Smith, T. P. L., & Bass, J. J. (1997) · Genome Research · doi:10.1101/gr.7.9.910 · Cited by 1,204 · cited 1×
“Spontaneous mutations in the myostatin gene that decrease myostatin expression result in hypermuscularity (7), whereas overexpression of myostatin results in muscle atrophy (8, 9).”
BackgroundFunctional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831
Myostatin negatively regulates satellite cell activation and self-renewal
McCroskery, S., Thomas, M., Maxwell, L., Sharma, M., & Kambadur, R. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200207056 · Cited by 784 · cited 1×
“The findings obtained in 13–16 mo-old mice and in Mstn / mice support the traditional belief that the primary effect of inhibiting myostatin is satellite cell activation through inhibition of the intracellular Smad signaling pathway (18).”
BackgroundSmad2 and 3 transcription factors control muscle mass in adulthood
Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., & Sandri, M. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00104.2009 · Cited by 517 · cited 1×
“Since myostatin signals through the Smad signaling pathway and activates the E3 ubiquitin ligases, MuRF-1, and atrogin-1 (MAFbx) (37), we examined the effect of PF-354 on mRNA expression of genes encoding for several of these proteins, as well as for myostatin.”
BackgroundApoptosis in skeletal muscle with aging
Dirks, A., & Leeuwenburgh, C. (2002) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00458.2001 · Cited by 377
Age-related differences in apoptosis with disuse atrophy in soleus muscle
Leeuwenburgh, C., Gurley, C. M., Strotman, B. A., & Dupont-Versteegden, E. E. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00576.2004 · Cited by 231 · cited 2×
“A previous study found that age-related increases in skeletal muscle apoptosis occurred predominantly in myofiber nuclei rather than interstitial nuclei (49), and so it is likely that the reduction in apoptotic index with PF-354 treatment reflects a reduction in apoptotic myonuclei.”
BackgroundMethodKoopman, R., Zorenc, A. H. G., Gransier, R. J. J., Cameron-Smith, D., & van Loon, L. J. C. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00530.2005 · Cited by 196 · cited 4×
“The improvement in functional capacity was due to fiber hypertrophy, with a 12% higher mean fiber CSA and a greater CSA of both type IIa and IIx/b fibers in TA muscles of PF-354-treated mice.”
MethodInfluentialSelf-citationLeBrasseur, N. K., Schelhorn, T. M., Bernardo, B. L., Cosgrove, P. G., Loria, P. M., & Brown, T. A. (2009) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp068 · Cited by 180
Cited by
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways
Rodriguez, J., Vernus, B., Chelh, I., Cassar-Malek, I., Gabillard, J. C., Hadj Sassi, A., Seiliez, I., Picard, B., & Bonnieu, A. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1689-x · Cited by 397
“mice show reduced sarcopenia compared to wild-type littermates [36] and antibody-mediated myostatin inhibition attenuates muscle fiber atrophy, enhances muscle functional capacity, and reduces apoptosis in skeletal muscles from aging mice [37].”
BackgroundAtrogin-1, MuRF-1, and sarcopenia
Gumucio, J. P., & Mendias, C. L. (2013) · Endocrine · doi:10.1007/s12020-012-9751-7 · Cited by 370
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314
Shan, T., Liang, X., Bi, P., & Kuang, S. (2013) · The FASEB Journal · doi:10.1096/fj.12-225755 · Cited by 301
Hsp72 preserves muscle function and slows progression of severe muscular dystrophy
Gehrig, S. M., van der Poel, C., Sayer, T. A., Schertzer, J. D., Henstridge, D. C., Church, J. E., Lamon, S., Russell, A. P., Davies, K. E., Febbraio, M. A., et al. (2012) · Nature · doi:10.1038/nature10980 · Cited by 250
Self-citationDong, J., Dong, Y., Dong, Y., Chen, F., Mitch, W. E., & Zhang, L. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.200 · Cited by 212
“increase the mRNAs and proteins of PGC-1α in skeletal muscles (17;45;46).”
BackgroundSarcopenic obesity and endocrinal adaptation with age
Sakuma, K., & Yamaguchi, A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/204164 · Cited by 189
Camporez, J.-P. G., Petersen, M. C., Abudukadier, A., Moreira, G. V., Jurczak, M. J., Friedman, G., Haqq, C. M., Petersen, K. F., & Shulman, G. I. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525795113 · Cited by 184
“However, a previous study (27) failed to show increased grip strength in aged mice (24 mo old) after 4 wk of treatment with an anti-myostatin antibody (PF-354), whereas another study (28) showed just increased in situ muscle strength of aged (21 mo old) mice treated with this same antibody for 14 wk.”
BackgroundFrom muscle wasting to sarcopenia and myopenia: update 2012
von Haehling, S., Morley, J. E., & Anker, S. D. (2012) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-012-0089-z · Cited by 177
“In addition, animal studies have recently reported beneficial effects of soluble activin receptor type IIB (ActRIIB) treatment [38] and myostatin inhibition [39].”
BackgroundLatres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T. B., Huang, Y., Eckersdorff, M., Rafique, A., Mastaitis, J., et al. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0060-8 · Cited by 143
Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass
Sakuma, K., & Yamaguchi, A. (2012) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-011-0052-4 · Cited by 137
Myostatin: more than just a regulator of muscle mass
Argilés, J. M., Orpí, M., Busquets, S., & López-Soriano, F. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.02.001 · Cited by 125
Nakayama, K. H., Quarta, M., Paine, P., Alcazar, C., Karakikes, I., Garcia, V., Abilez, O. J., Calvo, N. S., Simmons, C. S., Rando, T. A., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0416-4 · Cited by 113
Antibody-Directed Myostatin Inhibition Enhances Muscle Mass and Function in Tumor-Bearing Mice
Murphy, K. T., Chee, A., Gleeson, B. G., Naim, T., Swiderski, K., Koopman, R., & Lynch, G. S. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00121.2011 · Cited by 111
“a control, as it was used in each of the previously published studies utilizing PF-354 (32, 33, 35).”
BackgroundMethodSelf-citationAutophagy as a Potential Target for Sarcopenia: AUTOPHAGY REGULATION IN SARCOPENIA
Fan, J., Kou, X., Jia, S., Yang, X., Yang, Y., & Chen, N. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25260 · Cited by 101
Increased Muscle Force Production and Bone Mineral Density in ActRIIB-Fc-Treated Mature Rodents
Chiu, C.-S., Peekhaus, N., Weber, H., Adamski, S., Murray, E. M., Zhang, H. Z., Zhao, J. Z., Ernst, R., Lineberger, J., Huang, L., et al. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt030 · Cited by 68
Davey, J. R., Watt, K. I., Parker, B. L., Chaudhuri, R., Ryall, J. G., Cunningham, L., Qian, H., Sartorelli, V., Sandri, M., Chamberlain, J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85477 · Cited by 51
“The application of myostatin inhibition in the aged context has shown relatively minor improvements in muscle mass with an appreciable improvement in recovery from muscle injury (23, 40, 41), although of seemingly lesser magnitude than effects observed during treatment of young mice (42).”
ResultMaster Regulators of Muscle Atrophy: Role of Costamere Components
Gorza, L., Sorge, M., Seclì, L., & Brancaccio, M. (2021) · Cells · doi:10.3390/cells10010061 · Cited by 31
Diet and exercise in frailty and sarcopenia. Molecular aspects
Millan-Domingo, F., Garcia-Dominguez, E., Gambini, J., Olaso-Gonzalez, G., Viña, J., & Gomez-Cabrera, M. C. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101322 · Cited by 31
Phytoecdysteroids Do Not Have Anabolic Effects in Skeletal Muscle in Sedentary Aging Mice
Lawrence, M. M., Zwetsloot, K. A., Arthur, S. T., Sherman, C. A., Huot, J. R., Badmaev, V., Grace, M., Lila, M. A., Nieman, D. C., & Shanely, R. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18020370 · Cited by 11
“Inhibiting myostatin expression in aged mice is reported to decrease MAFbx mRNA levels, but not MuRF-1, and attenuate the loss of muscle mass [15].”
Background
Metadata
- Authors
- Murphy, K. T., Koopman, R., Naim, T., Léger, B., Trieu, J., Ibebunjo, C., & Lynch, G. S.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2010-07-12
- Volume
- 24
- Issue
- 11
- Pages
- 4433-4442
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1983415262
- Cited by
- 124
- References
- 11
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.